BioMediTech Research Groups

Cancer Biology

Group Leader: Professor Jorma Isola


About Us

Cancer Biology group. At IMT/BMT/MED at the University of Tampere since 1995

Jilab Inc (@Kauppi campus) since 2007

Research interests and expertise

Breast cancer biomarkers & Digital Pathology


Development of chromogenic in situ hybridization for breast cancer oncogenes  (CISH)

  • Pioneering scientific publications, patent and FDA-approval for a reagent kit

Development of ultrarapid Cytonel staining kit for intraoperative assessment of sentinel lymph node metastases

  • CE-IVD certified staining kit commercialized and sold for > 3m€ (2017)

Digital pathology

  • Pioneering work and publications of whole slide microscope imaging & image analysis software
  • Scanner & software commercialized via Jilab Inc.


Research Group of 5 people

Professor Jorma Isola is the founder and owner of biotechnology company Jilab Inc. (8 people)

Collaboration offer and requests

Contact prof. Jorma Isola, jorma.isola(at)

Major Publications

  1. Isola J, Holli K., Visakorpi T., Kallioniemi OP. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.  Journal of the National Cancer Institute 84:1109-1114,1992
  2. Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J Clin Oncol. 2006 Jun 1;24(16):2428-36. Epub 2006 May 8.
  3. Joensuu H, Kellokumpu-Lehtinen P, Bono P, Alanko T, Kataja V, Asola R, Utriainen T, Kokko R, Hemminki A, Tarkkanen M, Turpeenniemi-Hujanen T, Jyrkkiö S, Flander M, Helle L, Ingalsuo S, Johanssoon K, Jääskeläinen A-S, Pajunen M, Rauhala M, Kaleva-Kerola J, Salminen T, Leinonen M, Elomaa I, and Isola J. Docetaxel or Vinorelbine With or Without Trastuzumab As Adjuvant Treatments of Breast Cancer. New England Journal of Medicine 2006 Feb 23;354(8):809-20.
  4. Tuominen VJ, Ruotoistenmäki S, Viitanen A, Jumppanen M, Isola J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12(4):R56. doi: 10.1186/bcr2615. Epub 2010 Jul 27.
  5. Barok M, Joensuu H, Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014 Mar 5;16(2):209. doi: 10.1186/bcr3621.
© 2019 | BioMediTech Finland. All rights reserved.